01:55 PM EDT, 05/29/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our target to $134 from $115 based on our NPV analysis. We widen our 2024 loss per share (LPS) estimate to -$6.55 from -$6.21 and maintain our 2025 LPS view at -$5.24. Developments around the rise of the new Covid-19 variant "Flirt" with speculations of a potential summer surge, as well as news that the U.S. Health and Human Services Department (HHS) is talking to leading vaccine manufacturers for potential vaccines against the new bird flu strain H5N1, caused volatility in MRNA shares recently, in our view. Shares went up by 42% from May 10 to May 24 and are down by roughly 13% since the beginning of the week. We think that there is considerable uncertainty on both issues at this point and see the developments around the RSV vaccine's regulatory approval, for which MRNA expects an answer during this quarter, as the key event for the company in the near term. Given the risk of considerable event-driven swings in the stock price in the short run, we remain at Hold.